Genmab’s petosemtamab trial cuts death risk by 50% in cancer
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
More in Health & Medicine
Pinktober on two wheels: women-led Karachi rally takes breast cancer awareness to the streets
As Pinktober brings renewed attention to breast cancer awareness, a women-led motorcycle rally took to the streets of Karachi last Sunday, bringing together female riders, organisers and a medical…
Lilly shuffles business structure; Novartis writes off part of Avidity deal
Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.
STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
Missouri attorney general warned Eli Lilly to discontinue requiring hospitals to provide claims data to receive discounted medicines under 340B program
3 next-generation weight-loss drugs at different stages of FDA review and trials
The next weight-loss drugs to watch are CagriSema, retatrutide and aleniglipron, three obesity candidates at different stages of testing and FDA review, and only one has been filed
CSOs identify stigma, poor facilities as barriers to HIV, TB, malaria treatment in Akwa Ibo
Civil society groups and health workers in Akwa Ibom say stigma, cultural barriers, poor facilities and confidentiality concerns are keeping vulnerable residents from accessing HIV, TB and malaria…